Related Experiment Video
Updated: Dec 29, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.1K
The IL-15 / sIL-15Rα complex modulates immunity without effect on asthma features in mouse
Antoine Moui1,2, Martin Klein1, Dorian Hassoun1,2
1L'institut du thorax, Inserm, CNRS, Université́ de Nantes, Nantes, France.
Respiratory Research
|January 31, 2020
Summary
The IL-15/sIL-15Rα complex (IL-15Cx) modulates immune cells in asthma but does not improve lung function or airway remodeling. This suggests limited therapeutic potential alone for asthma treatment.
Area of Science:
- Immunology
- Respiratory Medicine
- Pharmacology
Background:
- Interleukin 15 (IL-15) is crucial for lymphocyte and natural killer cell function.
- The IL-15/soluble IL-15Rα complex (IL-15Cx) enhances IL-15 bioavailability and activity.
- IL-15Cx has been explored to mitigate IL-15-driven inflammation.
Purpose of the Study:
- To investigate the therapeutic potential of IL-15Cx in a mouse model of asthma.
- To assess the impact of IL-15Cx on airway inflammation, lung function, and bronchial remodeling.
Main Methods:
- A house dust mite-induced asthma model in mice was utilized.
- IL-15Cx was administered intraperitoneally after initial sensitization and challenge.
- Respiratory function, lung histology, and inflammatory cell populations were analyzed.
Main Results:
- IL-15Cx increased natural killer cells, CD8+ memory T cells, and regulatory cells systemically.
- No significant improvements were observed in bronchial hyperreactivity, remodeling, or cellular infiltrate.
- IL-15Cx limited bronchial mucus secretion and modulated inflammatory responses.
Conclusions:
- IL-15Cx demonstrated a limited impact on the overall immune response in this asthma model.
- The compound did not improve lung function or airway pathology in mice.
- These findings suggest IL-15Cx may have potential in combination therapies rather than as a standalone treatment.
Related Concept Videos
01:24T Cell Types and Functions
2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K